Codex Dna, Inc. DNAY
We take great care to ensure that the data presented and summarized in this overview for Codex DNA, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DNAY
View allLatest Institutional Activity in DNAY
Top Purchases
Top Sells
About DNAY
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Insider Transactions at DNAY
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 24
2024
|
James B Weissman |
BUY
Grant, award, or other acquisition
|
Direct |
8,390
+50.0%
|
-
|
Jul 24
2024
|
Michael R. Hodges |
BUY
Grant, award, or other acquisition
|
Direct |
8,390
+50.0%
|
-
|
Jul 24
2024
|
Sarah E. Hlavinka |
BUY
Grant, award, or other acquisition
|
Direct |
8,390
+50.0%
|
-
|
Jul 24
2024
|
Steven J Golub |
BUY
Grant, award, or other acquisition
|
Direct |
8,390
+50.0%
|
-
|
Jul 24
2024
|
Todd Krueger |
BUY
Grant, award, or other acquisition
|
Direct |
8,390
+50.0%
|
-
|
May 01
2024
|
Gregory J. Herrema |
BUY
Grant, award, or other acquisition
|
Direct |
31,486
+14.57%
|
-
|
May 01
2024
|
Jami K Nachtsheim |
BUY
Grant, award, or other acquisition
|
Direct |
34,297
+25.22%
|
-
|
May 01
2024
|
Christine A Tsingos |
BUY
Grant, award, or other acquisition
|
Direct |
37,109
+26.21%
|
-
|
May 01
2024
|
Annette Tumolo |
BUY
Grant, award, or other acquisition
|
Direct |
36,406
+18.75%
|
-
|
May 01
2024
|
Frank Witney |
BUY
Grant, award, or other acquisition
|
Direct |
48,354
+29.47%
|
-
|
Apr 17
2024
|
Eric Eugene Esser President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+43.62%
|
-
|
Mar 01
2024
|
Todd Robert Nelson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,756
-2.66%
|
$0
$0.53 P/Share
|
Mar 01
2024
|
Eric Eugene Esser President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,340
-10.25%
|
$0
$0.53 P/Share
|
Mar 01
2024
|
Daniel Glenn Gibson Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
656
-0.62%
|
$0
$0.53 P/Share
|
Mar 01
2024
|
Rob Cutler Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,376
-3.71%
|
$0
$0.53 P/Share
|
Feb 27
2024
|
Todd Robert Nelson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,776
-3.51%
|
$0
$0.53 P/Share
|
Feb 27
2024
|
Daniel Glenn Gibson Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,265
-2.22%
|
$0
$0.53 P/Share
|
Feb 27
2024
|
Rob Cutler Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,174
-8.54%
|
$0
$0.53 P/Share
|
Oct 18
2023
|
Gregory J. Herrema |
BUY
Grant, award, or other acquisition
|
Direct |
153,191
+50.0%
|
-
|
Jul 06
2023
|
Jami K Nachtsheim |
BUY
Grant, award, or other acquisition
|
Direct |
46,752
+40.96%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 330K shares |
---|
Payment of exercise price or tax liability | 19.3K shares |
---|